European Patent granted for BUPI STOCKHOLM, October 19,

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Oct 19, 2016 at 2:45 AM

European Patent granted for BUPI

STOCKHOLM, October 19, 2016 -- Moberg Pharma AB (OMX: MOB) announced that the European Patent Office (EPO) has issued Patent No. 2701681 which protects BUPI, currently in development for oral mucositis. The new patent covers pharmaceutical compositions comprising a local anesthetic, such as bupivacaine, for local administration to the mouth or throat. The patent also protects lozenge formulations of a local anesthetic for use in the treatment of oral mucositis in cancer patients. This patent is expected to provide coverage through at least 2031. Additional patent applications are pending in the United States and Canada. “This patent provides Moberg with important intellectual property protection for BUPI, our lozenge formulation of bupivacaine for pain management of oral mucositis in cancer patients,” commented Peter Wolpert, Moberg Pharma’s CEO. “This issuance of this patent is an important milestone for the BUPI development program and part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products.” Earlier in 2016, the Company announced positive Phase 2 results with BUPI in treating pain associated with oral mucositis in patients with head and neck cancer undergoing radiotherapy. The primary endpoint was met with high statistical significance. The Company is moving forward with one Phase 3 trial to be conducted in Europe, co-funded by a grant from Eurostars. A second Phase 3 study will be conducted in India, financed by Moberg’s partner Cadila Pharmaceuticals. The agreement with Cadila in combination with the Eurostars grant means that Moberg’s investment for the BUPI phase 3 program is substantially reduced. About this information This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 CET on October 19, 2016. About Oral Mucositis and BUPI Oral mucositis (“OM)” is a painful inflammation and ulceration of the mucous membranes lining the mouth. OM is a common and often debilitating complication of cancer treatment which affects 80% of patients with head and neck cancer receiving radiotherapy, almost all patients undergoing bone marrow transplantation, and a wide range of patients receiving chemotherapy. OM makes the patient less likely to comply with their cancer treatment, increases mortality and morbidity and contributes to rising health care costs. In the U.S., every year approximately 400 000 patients suffer from OM during cancer therapy. The patent protected BUPI technology encompasses novel lozenge formulations of bupivacaine, a local anesthetic with a well-established long acting effect, currently available on the market for other indications as an injectable. In Phase 2, the group treated with BUPI had 31% reduction in pain in mouth or pharynx compared to standard pain treatment (p=0.0032). The difference measured in the mouth only was even more pronounced - BUPI provided 50% additional pain reduction compared to standard treatment (p=0.0002). For additional information, please contact: Peter Wolpert, CEO, Phone: +46 707 35 71 35, E-mail: peter.wolpert@mobergpharma.se Kjell Rensfeldt, VP R&D, Phone: +46 707 12 4532, E-mail: kjell.rensfeldt@mobergpharma.se About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Domeboro®, Fiber Choice® and PediaCare®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (MOB.ST).

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Appy Pie Secures Patent for AI Driven App Building

A New Dawn in App Creation You ever think about a world where creating an app is as straightforward as chatting with an old buddy? Well, that future's knocking at the door, courtesy of Appy Pie. They're ruffling feathers with a shiny new U.S. patent promising just that—apps whipped into shape by a bit of chitchat with their AI-powered platform. It's got folks scratching...

Perkins Rolls Out Mahjong to Revive Family Bonds

Perkins Ditches the Phones, Sparks True Connection No doubt about it, folks—Perkins Restaurant & Bakery has cooked up something special to bring families back to the table. Not just for pancakes or pies this time, but for a little classic game action with their limited-edition Mahjong set. Love it or leave it, this is Perkins tapping into the magic of togetherness...

Gray's Rise in ENR Rankings Highlights Sector Dominance

Gray's Outstanding Reputation in the Construction Arena Nothing says “we're on top of our game” like snatching top slots in industry rankings, and that's precisely what Gray, the construction and engineering heavyweight, has managed to do. This firm recently secured impressive spots across ten different categories in the prestigious Engineering News-Record (ENR) Top...

Kansas Marijuana DUI Laws: What Drivers Must Know

Navigating the Legal Maze of Marijuana DUIs Marijuana DUI, ever heard of it? Many folks in Kansas might just find themselves scratching their heads. While booze clearly shouts 'DUI' when you hit the road sauced, the green stuff doesn’t dodge that same bullet. You better believe it, Kansas doesn’t mess around when it comes to drugs behind the wheel, and marijuana is...

Once Upon a Coconut Supports Breast Cancer Cause

Supporting Breast Cancer Awareness When a coconut water brand shifts to pink, it's not just about changing colors—it's a signal of commitment. Every October, the world paints itself pink to stand against breast cancer, and Once Upon a Coconut is no different. This year, they're diving headfirst into Breast Cancer Awareness Month with their limited-edition pink cans, all...

Nailah Thorbourne's Vlair Shapewear: Fashion Freedom

Fashion with a Punch: Nailah Thorbourne's New Venture You'd think from the way the fashion industry's been humming along that someone would've cracked the code on shapewear a long time ago, right? But alas, it takes Nailah Thorbourne to step out of Brick & Lace's spotlight and into this shapely market with Vlair Shapewear. Apparently, what most overlooked in comfort, she...

J.P. Morgan, Thunes Partner for Global Payment Integration

You don't need a crystal ball to see J.P. Morgan's playing the long game by teaming up with Thunes. In this world, where cash is digital and the reach is global, it's all about speed and scale—brushing elbows with the right partners makes all the difference. Sometimes it's about knowing when to hitch your wagon to a reliable workhorse, especially when global commerce is...

NUS Unveils eLuminator: A Leap for Robotics & Healthcare

Game-Changing Electronic Skin From NUS It's not every day you come across tech that could shake up multiple industries, but that's just what the National University of Singapore has cooked up with their latest brainchild—the eLuminator. This ain't your everyday wearable tech. We're talking a skin-like device that can both detect and show touch in real-time, no fiddly...

PVOLVE Expands Reach with New Franchises in 2026

The PVOLVE Fitness Craze Picks Up Momentum Seriously, if you hadn’t heard of PVOLVE before, now might be the time to get your ears in tune—and maybe consider hitting up one of their studios. They’ve been on an expansion tear, with franchise deals popping up like daisies in Washington and Wisconsin. It's the two new spots in Tacoma and Brookfield that are grabbing...

Klydoclock's Bold Move: Licensing International Boost

Revolutionizing Timekeeping with Art There’s this clock outfit, Klydoclock, that’s flipping the script on how we see time and art melding together. You see, they’ve taken those static old tick-tock reminders of the hour and juiced 'em up with animated art, turning your wall clock into something more akin to a mini art exhibit right in your living room. Ever heard of...